Research Consent Form (Pakistan)

A Research Consent Form in Pakistan confirms in writing the permission or release granted and the rights given up or relied on as a result.

The Contract Act 1872 (Act No. IX of 1872) provides the legal foundation for research consent in Pakistan. Section 14 of the Contract Act 1872 defines free consent as consent not caused by coercion, undue influence, fraud, misrepresentation, or mistake. A Research Consent Form in Pakistan must demonstrate that the participant's consent was freely given — without coercion from researchers, employers, or physicians — with full understanding of the research and its implications. Section 2(h) of the Contract Act 1872 defines a valid contract as an agreement enforceable by law, and the research consent relationship — though not a commercial contract — is governed by the same principles of free and informed consent. Section 19 of the Contract Act 1872 provides that consent obtained by coercion under Section 15 or undue influence under Section 16 renders the consent voidable at the option of the person whose consent was so obtained.

The Pakistan Health Research Council (PHRC), established under the Pakistan Health Research Council Act 1994 (amended in 2019), is the apex body responsible for promoting, coordinating, and overseeing health research in Pakistan. The PHRC's National Bioethics Committee (NBC) issues guidelines for ethical conduct of research in Pakistan, including requirements for informed consent. The NBC's 'Guidelines for Ethics in Research' (revised 2019) require that a research consent form be approved by an accredited Institutional Review Board (IRB) or Ethical Review Committee (ERC) before any research is conducted. The NBC maintains a registry of accredited IRBs at hospitals, universities, and research institutions across Pakistan.

For medical and clinical research conducted in Pakistan, additional regulatory oversight is provided by the Drug Regulatory Authority of Pakistan (DRAP), established under the Drug Regulatory Authority of Pakistan Act 2012. Clinical trials involving investigational drugs, devices, or biologics require DRAP approval under the DRAP's Clinical Trial Regulations and must comply with Good Clinical Practice (GCP) guidelines — the ICH E6 guidelines adopted by DRAP — which prescribe detailed requirements for informed consent documentation in clinical trials. DRAP requires clinical trial consent forms to be submitted as part of the trial protocol and approved before the trial commences at any site in Pakistan.

Social science research, academic research conducted by universities under the Higher Education Commission of Pakistan (HEC), and market research conducted by commercial research firms operate under PHRC and HEC guidelines for research ethics, as well as their institutional IRB requirements. The Higher Education Commission (HEC) of Pakistan, established under the Higher Education Commission Ordinance 2002, has issued research ethics guidelines requiring all HEC-affiliated universities — including University of the Punjab, University of Karachi, Quaid-i-Azam University, NUST, COMSATS, IBA, and LUMS — to establish IRBs or ERCs and to require informed consent for all research involving human participants. HEC's Pakistan Research Repository (PRR) requires evidence of ethical approval for all theses submitted to it.

The Research Consent Form in Pakistan must be written in a language and at a reading level accessible to the research participant — for studies conducted in rural areas or with non-English-speaking populations, the consent form must be translated into Urdu, Punjabi, Sindhi, Pashto, or other relevant regional languages. The NBC guidelines require that the consent process be conducted in the participant's preferred language. For multi-site research involving communities across different provinces, the consent form may require translation into multiple languages with back-translation to verify accuracy.

The Prevention of Electronic Crimes Act 2016 (PECA) is relevant to research consent forms in the context of online and digital research — where consent is collected electronically, the researcher must comply with PECA's provisions on electronic records and must not collect personal data through deceptive means. The pending Personal Data Protection Bill in Pakistan, modelled in part on the European Union's General Data Protection Regulation (GDPR), will when enacted impose additional obligations on researchers handling participants' personal data — requiring consent for data collection, processing, and storage, and granting participants rights of access, correction, and deletion of their personal data.

A Research Consent Form in Pakistan is required whenever a researcher — whether at a university, hospital, research institute, or commercial organisation — wishes to involve human participants in a research study, to satisfy ethical, legal, and institutional requirements before data collection begins. The consent form is not a bureaucratic formality — it is the legal and ethical anchor of the researcher-participant relationship, confirming the voluntariness of participation under the Contract Act 1872 and the NBC's ethical guidelines.

A Research Consent Form is needed for all clinical research studies — drug trials, device studies, vaccine studies, surgical procedure research — conducted in Pakistan under DRAP oversight. The DRAP's Clinical Trial Regulations require signed informed consent from each participant before any research procedure is performed. This includes Phase I, II, III, and IV clinical trials conducted at hospitals affiliated with Pakistan's major medical universities — Aga Khan University Hospital, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Jinnah Postgraduate Medical Centre (JPMC), King Edward Medical University (KEMU), and Dow University of Health Sciences — all of which operate accredited IRBs under the PHRC National Bioethics Committee framework.

A Research Consent Form is required for academic research studies conducted by students and faculty at HEC-recognised universities — Quaid-i-Azam University Islamabad, University of Karachi, LUMS Lahore, NUST Islamabad, COMSATS University, and others — whenever the research involves interviews, surveys, focus groups, observations, or any other interaction with human participants. The university IRB or ERC requires the approved consent form before the research commences. Graduate students at HEC-affiliated universities conducting thesis research involving human subjects must obtain IRB approval and execute consent forms with each participant before beginning data collection.

A Research Consent Form is needed for social science and public health research — surveys on health behaviours, poverty, gender, education, or political attitudes — conducted by domestic research organisations such as Gallup Pakistan, IPSOS Pakistan, and the Social Policy and Development Centre (SPDC), or by international organisations including WHO, UNICEF, World Bank, and USAID operating research programmes in Pakistan.

A Research Consent Form is required for market research studies — consumer surveys, focus groups, product testing, and usability testing — conducted by commercial market research agencies for their clients. Participants in such research must consent to recording, video, or audio capture and to the use of their responses in client reports. Under the Pakistan Electronic Media Regulatory Authority (PEMRA) Ordinance 2002, recordings of identifiable persons require consent before broadcast or publication.

A Research Consent Form is needed when researchers plan to collect and process biological samples — blood, saliva, tissue — from participants in Pakistan. The NBC's bioethics guidelines require specific consent for biological sample collection, genetic analysis, and storage in biobanks. The Human Organ Transplant Act 2010 and the NBC guidelines impose strict requirements on consent for tissue collection, prohibiting collection from living donors without free and informed written consent.

A Research Consent Form is required when research involves minors under 18 years — in Pakistan, a person under 18 lacks full contractual capacity under the Contract Act 1872 (Section 11), and parental or guardian consent must be obtained in addition to the child's assent (where the child is old enough to understand). The form must be signed by the parent or legal guardian, whose authority is confirmed by the child's birth certificate issued by NADRA or the Union Council, or the guardian's appointment by a court under the Guardian and Wards Act 1890.

A Research Consent Form is needed for research involving vulnerable populations — prisoners held in institutions under the Prisons Act 1894, patients with mental illness under the Mental Health Ordinance 2001, the economically disadvantaged, or Afghan and other refugees — where special protections apply under the PHRC National Bioethics Committee guidelines to prevent exploitation of participants who may be unable to exercise genuinely free consent due to their circumstances of dependence, deprivation, or power imbalance.

A valid Research Consent Form in Pakistan compliant with the PHRC National Bioethics Committee guidelines, the Declaration of Helsinki, and the Contract Act 1872 must contain the following essential elements. Forms-legal.com provides this Research Consent Form (Pakistan) template to support researchers in meeting their ethical and legal obligations to participants.

Study Title and Sponsor: The full title of the research study, the name and address of the principal investigator (PI) and the institution conducting the research, and the name of the sponsor (if any) — pharmaceutical company, government body, international organisation such as WHO or World Bank. The IRB or ERC approval reference number and date of approval must be stated. For DRAP-regulated clinical trials, the DRAP trial registration number issued by the Pakistan National Health Research Data Repository (NHRD) must be included.

Purpose of Research: A clear, non-technical explanation of why the research is being conducted — what question the study aims to answer, what benefits the research may produce for society, and how the participant's involvement contributes to the study's goals. The purpose must be accurate and not misleading under Section 17 of the Contract Act 1872 (prohibition of misrepresentation). A consent form that conceals the true research purpose or misrepresents the study's commercial intent vitiates the informed consent and may constitute fraud under the Contract Act 1872.

Participation Procedures: A step-by-step description of what participation involves — the number and duration of study visits, the procedures to be performed (interviews, surveys, blood draws, imaging, physical examination), the total time commitment, and any follow-up required. Procedures must be described in plain Urdu or the participant's language where required by NBC guidelines. Randomisation procedures in clinical trials must be explained — the participant must understand that they may receive either the experimental treatment or a placebo.

Risks and Discomforts: An honest disclosure of all foreseeable risks, discomforts, or inconveniences associated with study participation — physical, psychological, social, or financial. Under the Declaration of Helsinki (Principle 16), the importance of the research objective must be weighed against the risks and burdens to participants. Researchers must not minimise or conceal risks to encourage participation. The PHRC NBC guidelines require researchers to describe the probability and severity of each identified risk and the measures taken to minimise them.

Benefits: A balanced statement of any direct benefits to the participant (if any) and the potential indirect benefits to society. Consent forms in Pakistan must not promise speculative or exaggerated benefits — false promises of benefit constitute misrepresentation under Section 17 of the Contract Act 1872, vitiating the consent. The distinction between medical care provided as part of the study and medical care available to non-participants must be clearly stated.

Confidentiality and Data Protection: A clear statement of how participant information will be stored (anonymised, coded, password-protected), who will have access to identifiable data, how long data will be retained, and whether data may be shared with other researchers or regulatory authorities (DRAP for clinical trial data, HEC for research data archiving). Given the pending Personal Data Protection Bill in Pakistan, researchers should adopt data minimisation and purpose limitation principles consistent with the PHRC guidelines and the Electronic Transactions Ordinance 2002.

Voluntary Participation: A prominent statement — in bold or underlined text — that participation is entirely voluntary. The participant has the right to refuse to participate and to withdraw from the study at any time without penalty, without loss of any benefits to which they are otherwise entitled, and without affecting their relationship with the researcher's institution — particularly important in hospital-based research at JPMC, KEMU, or Aga Khan University Hospital where participants may fear affecting their medical care if they decline or withdraw.

Compensation: If participants receive any payment, transport reimbursement, or other compensation for participation, the amount and payment schedule must be stated. Compensation must not be so high as to constitute undue inducement — the NBC guidelines and the Declaration of Helsinki caution against payment levels that compromise the voluntariness of consent. Under Section 16 of the Contract Act 1872, consent obtained through financial pressure that undermines free will may constitute undue influence.

Contact Information: Names and contact details of the principal investigator, the IRB/ERC chair, and the institution's research ethics office — three separate contacts to whom participants can address questions about the research, their rights, or concerns about research misconduct. The provision of multiple independent contacts is required by NBC guidelines and allows participants to escalate concerns without going through the research team itself.

Consent Declaration: The participant's signed declaration: 'I have read (or had read to me) the above information. I have had the opportunity to ask questions. I voluntarily agree to participate in this study. I understand that I may withdraw at any time without penalty.' Signature line, printed name, CNIC number (NADRA 13-digit format), date, and — for low-literacy participants — a thumbprint with a witness signature. The CNIC number links the consent to the participant's verified identity.

Parental Consent Block (for minors): Where the participant is under 18, a separate block for the parent or legal guardian — name, CNIC number, relationship to minor, signature, and date — is mandatory under PHRC guidelines and the Contract Act 1872 (Sections 11 and 68 on capacity to contract and beneficial contracts for minors). The guardian's authority should be confirmed by reference to the child's birth certificate or a court-issued guardianship order under the Guardian and Wards Act 1890.

Witness Block (for low-literacy participants): Where the participant cannot read, a literate impartial witness — not a member of the research team — must be present throughout the consent process, sign the form confirming that the information was read and explained accurately, and witness the participant's thumbprint. This procedure, required by NBC guidelines and the Declaration of Helsinki (Principle 25), protects both the participant and the researcher against later challenges to the validity of consent.

Language Certification: Where the consent form is in Urdu or a regional language, a certification by the translator confirming accurate translation from the original English version, and attestation by the IRB that the translated form was reviewed for comprehensibility by a native speaker of the target language.